Control and Related Parties

Control and Related Parties

Figures converted from IDR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

CPIN is 55.53%-controlled by the Jiaravanon family's Charoen Pokphand group, and the group is paid every year. The largest recurring channel is a brand royalty to a group entity in Singapore — $42.9m in FY2025, up 15% since FY2022 and rising whether profits climb or fall [1]. It is disclosed, labelled arm's-length, and bounded at about 1% of sales — but it is a senior, pro-cyclical claim that minority holders own around, and it takes a far bigger bite of profit in a trough than at a peak.

Who controls the company

At 31 December 2025 one holder, PT Charoen Pokphand Indonesia Group, owned 9,106,385,410 shares — 55.53% of the 16,398,000,000 outstanding. UBS AG Singapore held 5.98% and the public float below 5% each accounted for 38.49% [2]. That parent sits under Thailand's Charoen Pokphand group, controlled by the Jiaravanon family; CPIN is its Indonesian listed vehicle (Competitive Moat).

Control runs through the board as well as the register. Indonesia's two-tier structure separates an executive Board of Directors from a supervisory Board of Commissioners, and CPIN's executive board carries no independent members; two of the four commissioners are independent [3]. The six directors are long-tenured insiders — the President Director, Tjiu Thomas Effendy, joined in 1980 — and the audit committee is chaired by an independent commissioner who spent 1976–2008 inside the company, latterly as VP Finance Controller. This is a controlled company by any definition; the governance question is not whether the family sets strategy but how much value moves to it outside the ordinary dividend, and whether that flow is fair.

The royalty

The clearest such flow is a brand-and-technology royalty. Since a 2009 license agreement — novated in 2017 to Nugen Bioscience International Pte. Ltd. of Singapore, an entity under common control with the CP group — CPIN has paid a royalty for the intellectual property behind its products [4]. In FY2025 the charge was $42.9m, booked to general-and-administrative expense and equal to 30.9% of the group's total related-party expenses [5]. Around 1% of net sales leaves the consolidated group each year for the parent's brand.

The absolute number grows every year regardless of the cycle: $40.4m in FY2022, $41.9m in FY2023, $43.2m in FY2024, $42.9m in FY2025 (the FY2025 dip reflects a weaker year-end rupiah, not a smaller charge) [6] [7].

Source: Note 34/35 of the FY2023–FY2025 audited consolidated statements [8] [9] [10].

Because the royalty barely moves while pre-tax profit swings across the poultry cycle, its share of earnings is counter-cyclical to profit — largest when profit is smallest. The same ~$40m was 9.3% of pre-tax profit in the record FY2025 but 21.5% in the FY2023 trough. For a business whose downstream spread is set by government supply policy rather than the company (Downstream Cycle), the royalty behaves like a fixed senior charge ahead of minority earnings, heaviest exactly when profit is thinnest.

In the FY2023 trough feed earned $267m — 104% of group segment result while the downstream lost $9m — and that same year the fixed CP-group brand royalty took $42m, 21.5% of pre-tax profit versus 9.3% at the FY2025 peak, so the feed floor and the royalty's bite peak together in the year profit is thinnest [[11]](https://cpin-pro-f08764-usd-ira-ai.vercel.app/api/source-pdf?x=eyJobCI6W3sicCI6MTE5LCJyIjpbWzAuMDc0NzUsMC4xNzQ5OSwwLjc3MjY2LDAuMTg3MTJdXSwidCI6Ikhhc2lsIHNlZ21lbiA0LjExMy40MzYgKDQyMC4zMDApICgzMDEuNTYwKSA1ODAuMjcwICg3LjA2MCkgLSAzLjk2NC43ODYgU2VnbWVudCByZXN1bHRzIn1dLCJwYWdlIjoxMTksInJlbCI6InF1YXJ0ZXJseV9yZXBvcnRzL1E0X0ZZMjAyMy9DUElOX3Jlc3VsdHNfUTRfRlkyMDIzLnBkZiIsInJ1biI6IlBUX0NoYXJvZW5fUG9rcGhhbmRfSW5kb25lc2lhX1Ria19wcm9fcmVxMjc2In0 "PT Charoen Pokphand Indonesia Tbk — FY2023 Consolidated Financial Statements (audited) (Feed Economics).

Source: derived from the royalty note and consolidated pre-tax profit, FY2022–FY2025 audited statements [12] [13].

Two calibrations keep this in proportion. First, the royalty is a real economic input — the CP brand, breeding genetics, and technology are the same assets that underwrite the moat, so some payment for them is legitimate, not a pure transfer. Second, at roughly 1% of sales the charge is not large enough on its own to reset the investment case. What it does is lower the effective earnings minorities own by a near-fixed amount every year, and worsen the trough — a reason the mid-cycle multiple deserves a modest control discount rather than a clean read of reported EPS (Pricing the Cycle).

The recurring trade with the group

Beyond the royalty, CPIN buys raw materials from CP-affiliated suppliers in the ordinary course. In FY2025 these purchases totalled $196.9m — 4.63% of net sales, up from $169.2m (4.78%) in FY2024 — concentrated in a handful of common-control names [14].

Source: FY2025 audited consolidated statements, Note 34 — purchases of raw materials from entities under common control [15].

These are disclosed as priced on "agreed" terms, and each line is reported against its share of sales — but they are not independently repriced, so a slice of feed input cost is set within the group. At under 5% of sales the exposure is contained, and it has been stable as a proportion; the item to watch is whether that share climbs, which would move margin-setting further inside the family.

The frozen related-party receivable

Where related-party credit went wrong is small but instructive. CPIN carries $15.4m of amounts due from group affiliates, of which $8.9m is owed by PT Central Proteina Prima Tbk — CP's separately-listed shrimp arm — against which the group holds a $12.1m allowance for impairment, essentially unchanged from FY2024 [16]. About four-fifths of the balance is written down and static, leaving $3.3m net. Management states the allowance is adequate to cover non-collection [17]. The amount is immaterial to a $339m-profit company, but it is a reminder that intra-group credit to a weaker CP affiliate can sit frozen on the balance sheet for years rather than being repaid or forgiven cleanly.

Sources: FY2025 audited consolidated statements, Note 34 [18] [19] [20] [21].

What does not leak

Three things a skeptic would reach for turn out to be benign, and saying so is part of an honest read.

The affiliated asset purchases look alarming until you read the counterparties. In FY2023 CPIN bought poultry slaughterhouses, land, and equipment across ten provinces for $24.3m, plus $3.0m of land — but the sellers (PT Mitra Sinar Jaya and five others) are its own 100%-indirectly-owned subsidiaries, so the transaction is an internal reorganization that nets out in consolidation, not a purchase from the parent [22]. In FY2025 the company disclosed no material and no conflict-of-interest transactions at all [23].

Trade-receivable credit quality is ordinary, not stretched. The allowance against third-party trade receivables is $17.0m on $175.5m gross — about 9.7%, and down slightly from FY2024 — with related-party trade receivables a trivial $0.9m [24]. The plasma-farmer partnership model does not appear to be hiding an uncollectible book.

And key-management pay is modest for the size. Directors and commissioners were paid $11.4m in gross compensation in FY2025, up 25.8% on FY2024 but still only about 3.4% of net profit, with no equity awards [25]. The controlling family is compensated mainly as a shareholder, through the dividend it receives pari passu with the float — roughly $98m of the $177m FY2025 declaration on its 55.53% stake — not through pay.

Pricing the control discount

The evidence points to a control structure that is real but restrained. The family sets strategy through a family-and-insider board, and it extracts a steady brand royalty of about 1% of sales that grows every year and bites hardest in the trough; beyond that, the disclosed leakage is bounded — ordinary-course purchases under 5% of sales, a small frozen affiliate receivable, modest pay, and pari-passu dividends. That profile argues for a modest discount to the mid-cycle multiple for governance, not the deep discount a genuine tunneling case would demand.

The strongest fact against a benign read is that none of the group flows are independently repriced: the royalty rate, the transfer prices on $197m of purchases, and the terms of intra-group credit are all set inside a structure the family controls, and disclosure confirms the amounts without testing their fairness. What would change the read in either direction is observable in the same Note 34 each year — a step-up in the royalty beyond inflation, a rising related-party share of purchases, or a new large advance to a CP affiliate would signal value moving toward the parent; their continued stability would confirm that, so far, it is not.